Analysts Set Globus Medical, Inc. (NYSE:GMED) PT at $101.77

Shares of Globus Medical, Inc. (NYSE:GMED) have earned an average recommendation of “Moderate Buy” from the seventeen ratings firms that are presently covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a hold recommendation, nine have assigned a buy recommendation and three have issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $101.7692.

GMED has been the subject of a number of analyst reports. Wall Street Zen downgraded Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Wells Fargo & Company lowered their target price on shares of Globus Medical from $103.00 to $99.00 and set an “overweight” rating for the company in a research note on Friday, August 7th. UBS Group assumed coverage on shares of Globus Medical in a report on Tuesday, July 28th. They issued a “neutral” rating and a $82.00 target price on the stock. Needham & Company LLC lifted their price objective on Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Finally, Stifel Nicolaus dropped their price objective on Globus Medical from $95.00 to $80.00 and set a “hold” rating on the stock in a research note on Wednesday, July 8th.

Insiders Place Their Bets

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of Globus Medical stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $80.76, for a total value of $2,019,000.00. Following the completion of the sale, the director directly owned 510,175 shares in the company, valued at approximately $41,201,733. The trade was a 4.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 18.38% of the company’s stock.

Hedge Funds Weigh In On Globus Medical

Institutional investors and hedge funds have recently made changes to their positions in the stock. Invesco Ltd. increased its position in Globus Medical by 1,235.2% in the 4th quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company’s stock valued at $339,322,000 after buying an additional 3,595,339 shares in the last quarter. Bank of Montreal Can boosted its holdings in Globus Medical by 15,317.1% in the fourth quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company’s stock worth $294,519,000 after acquiring an additional 3,351,380 shares in the last quarter. Alliancebernstein L.P. grew its stake in Globus Medical by 1,303.9% in the third quarter. Alliancebernstein L.P. now owns 2,055,183 shares of the medical device company’s stock valued at $117,700,000 after acquiring an additional 1,908,795 shares during the period. Fuller & Thaler Asset Management Inc. acquired a new stake in Globus Medical in the fourth quarter valued at approximately $90,411,000. Finally, Norges Bank bought a new stake in shares of Globus Medical during the fourth quarter valued at approximately $89,922,000. Institutional investors own 95.16% of the company’s stock.

Globus Medical Stock Performance

Shares of NYSE:GMED opened at $85.75 on Monday. Globus Medical has a 52 week low of $54.15 and a 52 week high of $101.40. The firm has a market cap of $11.51 billion, a PE ratio of 21.93, a price-to-earnings-growth ratio of 1.38 and a beta of 0.95. The firm’s fifty day moving average is $79.98 and its 200-day moving average is $84.95.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Thursday, August 6th. The medical device company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.24. The business had revenue of $789.61 million during the quarter, compared to the consensus estimate of $782.88 million. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%.Globus Medical’s quarterly revenue was up 5.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.86 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Sell-side analysts forecast that Globus Medical will post 4.99 EPS for the current year.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.